Cyclic peptide TCCP-1 demonstrates potent antibacterial activity against Gardnerella vaginalis with low cytotoxicity
Background
Bacterial vaginosis (BV), a common vaginal dysbiosis primarily caused by Gardnerella vaginalis, presents a significant global health concern. Current conventional antibiotics often fail due to increasing resistance and high recurrence rates, necessitating novel therapeutic strategies. Antimicrobial peptides (AMPs) offer a targeted, resistance-sparing alternative due to their broad-spectrum activity and distinct mechanisms of action, such as bacterial membrane disruption. This study explores plant-derived AMPs as a potential solution to address these treatment gaps.
Study Design
Researchers computationally designed two antimicrobial peptides, TCCP-1 (a cyclic peptide) and ZMLP-2 (a linear peptide), from proteome sequences of Thymbra capitata and Zataria multiflora. These peptides were chemically synthesized and then rigorously evaluated for their antibacterial activity, cytotoxicity, hemolytic effects, and mechanism of action against Gardnerella vaginalis. Key assays included MIC determination for antibacterial potency and cell viability assays to assess host cell toxicity.
Results
The cyclic peptide TCCP-1 exhibited significant antibacterial activity against G. vaginalis, with a minimum inhibitory concentration (MIC) of 1.95 µg/mL. Crucially, TCCP-1 showed minimal cytotoxicity, maintaining high cell viability even at concentrations as high as 100 µg/mL, which is substantially above its MIC. In contrast, ZMLP-2, the linear AMP, displayed weaker antimicrobial activity with an MIC of 100 µg/mL and caused a moderate reduction in cell viability (~70-75%) at 100 µg/mL or below its MIC. Both peptides were found to disrupt bacterial membranes, a common mechanism for AMPs that supports the re-establishment of healthy vaginal flora. This membrane disruption mechanism is critical for their efficacy. > TCCP-1 demonstrated efficient antimicrobial activity against G. vaginalis along with decreased cytotoxicity, making it an excellent candidate for future in vivo studies and possible clinical uses.
Key Findings
- Cyclic peptide TCCP-1 showed potent antibacterial activity against G. vaginalis with an MIC of 1.95 µg/mL.
- TCCP-1 exhibited minimal cytotoxicity, maintaining high cell viability even at 100 µg/mL.
- Linear peptide ZMLP-2 had weaker activity (MIC 100 µg/mL) and moderate cytotoxicity (~70-75% viability at 100 µg/mL).
- Both TCCP-1 and ZMLP-2 disrupt bacterial membranes, a key mechanism of action.
Why It Matters
This research highlights TCCP-1 as a highly promising candidate for treating Bacterial Vaginosis, offering a novel, targeted approach that could overcome the limitations of conventional antibiotics, including resistance and recurrence. Developing plant-derived AMPs like TCCP-1 could provide a sustainable and effective alternative for BV prevention and treatment. While currently an in vitro finding, its potent activity and low cytotoxicity suggest a favorable safety profile for future preclinical and clinical development. This opens avenues for new topical or systemic protocols for BV, potentially reducing the burden of this prevalent condition.
gardnerella vaginalis
bacterial vaginosis
antimicrobial peptide
tccp-1
in vitro
cyclic peptide